We are making significant progress toward replenishing supply of the 0.25 mg, 0.5 mg and 1.0 mg doses for Wegovy™. While we do anticipate ongoing delays at the 1.7 mg dose, as well as the 2.4 mg maintenance dose throughout the remainder of the year, we remain on track to stabilize Wegovy™ supply in early 2022. However, people may continue to experience delays from time to time in filling prescriptions for Wegovy™ at local retail pharmacies. You can reach us at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday if you have questions or feedback – and select option 0 for more support. Read on for more details and please share any questions you may have. Thank you for your patience.
Since we made Wegovy™ available, there has been an unprecedented
demand for this medicine, which led to the current supply shortage.
To everyone affected, we want you to know we are doing all we can
to make this right and that supporting you is our top
priority. We will continue to provide up-to-date information on
our progress toward restoring supply.
There are five doses of Wegovy™ – the first four increase in a stepwise manner (starting with 0.25 mg, then 0.5 mg, 1.0 mg and 1.7 mg) until the fifth, maintenance dose (this full dose of 2.4 mg is intended for the fifth month of treatment and onwards.)
However, people may continue to experience delays from time to time in filling prescriptions for Wegovy™ at local retail pharmacies.
Our teams are working 24/7, however, making this medicine is a
complex process that requires multiple steps and facilities, in both
the United States and overseas. First, we produce the active
ingredient in Wegovy™, which is then filled and assembled into the
device it comes in. Finally, it’s packaged and sent out to a
distribution center, and then to wholesalers who distribute to retail
If you have received Wegovy™, we expect that you will now likely be able to get your initial 0.25 mg starting dose prescription filled.
It is important to know and consider that you may experience disruptions in getting the 1.7 mg dose as well as the 2.4 mg maintenance dose throughout the remainder of the year.
Please follow the dose escalation schedule in the Prescribing Information for Wegovy™. Importantly, the final decision as to whether and how you take this medication should be made together with your healthcare provider. For more information about the Wegovy™ dosing schedule, click here for the Prescribing Information and Medication Guide.
The staff at your local pharmacy are best suited to provide information about the availability of Wegovy™ at their store – at the starting 0.25 mg dose, as well as the subsequent four doses. We still recommend contacting them about your refills at least 1-2 weeks earlier than you normally would.
See a video from Dr. Jason Brett, executive director, medical affairs, obesity, Novo Nordisk Inc., who answers some of the key questions many of you have shared with us.
Wegovy™ is a prescription medicine indicated for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems to help them lose weight and keep it off used with a reduced-calorie meal plan and increased physical activity.
Please see below for important information, and don’t hesitate to call 1-833-4-WEGOVY (1-833-493-4689) and select option 0 for more support. You are our number one priority and we’re here to help.
If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. We will be reviewing that information on an ongoing basis and making periodic updates to this page. Please know that we take our responsibility to support you in this journey very seriously and are addressing this issue as a top priority. Thank you for your patience as we work to resolve this issue – which we will.
Your Career Guide